Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Alkermes (ALKS) has announced it will host a conference call and webcast on February 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2024 financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes (ALKS) has announced it will host a conference call and webcast on February 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2024 financial results. During the presentation, management will also outline financial expectations for 2025 and provide a company update.
The event will be accessible through the company's website investor section, with a conference call available at +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international participants. A replay will be available approximately two hours after the event.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -0.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-feb-12-2025-302368996.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.